Literature DB >> 12438333

Dynamics of gamma interferon, interleukin-12 (IL-12), IL-10, and transforming growth factor beta mRNA expression in primary Mycobacterium bovis BCG infection in guinea pigs measured by a real-time fluorogenic reverse transcription-PCR assay.

Mamoru Kawahara1, Tadashi Nakasone, Mitsuo Honda.   

Abstract

The guinea pig has been utilized as a model for studying infectious diseases because its reactions closely resemble those of humans biologically and immunologically. However, the cytokine responses in this animal remain to be studied. Initially, we established a quantitative assay using a real-time reverse transcription-PCR (RT-PCR) to measure guinea pig gamma interferon (IFN-gamma), interleukin-12 (IL-12), IL-10, and transforming growth factor beta (TGF-beta) mRNA. By preparing primer-fluorogenic probe sets for these cytokines and standard RNA templates corresponding to the target sequence of each cytokine, we obtained linear standard curves essential for quantitative determination. In guinea pigs immunized by intradermal (i.d.) vaccination with the Tokyo strain of Mycobacterium bovis BCG (0.1 mg) or else hyperimmunized with the same vaccine (10 mg) given intravenously (i.v.), peripheral blood mononuclear cells (PBMCs) at 4 weeks showed an increase in IFN-gamma mRNA expression in the latter but not the former animals. However, at week 10, IFN-gamma mRNA expression was markedly elevated in PBMCs, spleen cells, and cells in bronchoalveolar lavage fluid in both the i.d.- and the i.v.-immunized animals, the level of expression being 10 times higher in the latter. In contrast, the expression levels of IL-12 mRNA in PBMCs, spleen cells, and BAL cells were not enhanced in either group at 10 weeks postimmunization. The expression of IL-10 and TGF-beta increased slightly only in PBMCs. Regardless of differences in the levels of cytokine responses, the magnitudes of the purified protein derivative of tuberculin-specific delayed-type hypersensitivity (DTH) skin reactions for the two groups did not differ significantly at 8 weeks postvaccination. In this study, we quantitatively measured IL-10, IL-12, TGF-beta, and IFN-gamma mRNA in BCG-immunized guinea pigs and showed that the level of IFN-gamma mRNA expression does not necessarily reflect the magnitude of the DTH response, suggesting that there may be an intricate relationship between protective immunity, the level of IFN-gamma, and the DTH response. Thus, our quantitative assay would be of use for the development of vaccines using guinea pig models.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438333      PMCID: PMC132987          DOI: 10.1128/IAI.70.12.6614-6620.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Chemoprophylaxis with isoniazid against aerogenic tuberculous infection in the guinea pig.

Authors:  M L COHN; C L DAVIS; G MIDDLEBROOK
Journal:  Am Rev Respir Dis       Date:  1962-07

2.  Elevated chemokine levels in bronchoalveolar lavage fluid of tuberculosis patients.

Authors:  K Kurashima; N Mukaida; M Fujimura; M Yasui; Y Nakazumi; T Matsuda; K Matsushima
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

3.  Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production.

Authors:  C S Hirsch; R Hussain; Z Toossi; G Dawood; F Shahid; J J Ellner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

4.  Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine.

Authors:  M Jackson; S W Phalen; M Lagranderie; D Ensergueix; P Chavarot; G Marchal; D N McMurray; B Gicquel; C Guilhot
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  Conservation of a CD1 multigene family in the guinea pig.

Authors:  C C Dascher; K Hiromatsu; J W Naylor; P P Brauer; K A Brown; J R Storey; S M Behar; E S Kawasaki; S A Porcelli; M B Brenner; K P LeClair
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

6.  Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination.

Authors:  R Cheynier; S Gratton; M Halloran; I Stahmer; N L Letvin; S Wain-Hobson
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

7.  Protection against Mycobacterium tuberculosis infection by CD8+ T cells requires the production of gamma interferon.

Authors:  R E Tascon; E Stavropoulos; K V Lukacs; M J Colston
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

8.  Effects of modulating TGF-beta 1 on immune responses to mycobacterial infection in guinea pigs.

Authors:  G Dai; D N McMurray
Journal:  Tuber Lung Dis       Date:  1999

9.  Spontaneous cytokine gene expression in normal guinea pig blood and tissues.

Authors:  A M Scarozza; A I Ramsingh; V Wicher; K Wicher
Journal:  Cytokine       Date:  1998-11       Impact factor: 3.861

10.  Mycobacterium bovis bacille Calmette-Guérin enhances pathogenicity of simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis.

Authors:  D Zhou; Y Shen; L Chalifoux; D Lee-Parritz; M Simon; P K Sehgal; L Zheng; M Halloran; Z W Chen
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

View more
  9 in total

1.  High-level cellular and humoral immune responses in Guinea pigs immunized intradermally with a heat-inactivated varicella-zoster virus vaccine.

Authors:  Julia Sarkadi; Mate Jankovics; Kinga Fodor; Zoltan Kis; Maria Takacs; Ildiko Visontai; Istvan Jankovics; Eva Gonczol
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

2.  Development of a guinea pig immune response-related microarray and its use to define the host response following Mycobacterium bovis BCG vaccination.

Authors:  Julia A Tree; Michael J Elmore; Sajid Javed; Ann Williams; Philip D Marsh
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

3.  In situ study of abundant expression of proinflammatory chemokines and cytokines in pulmonary granulomas that develop in cynomolgus macaques experimentally infected with Mycobacterium tuberculosis.

Authors:  Craig L Fuller; JoAnne L Flynn; Todd A Reinhart
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

4.  A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.

Authors:  Baolin Wang; Marcela Henao-Tamayo; Marisa Harton; Diane Ordway; Crystal Shanley; Randall J Basaraba; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2007-07

Review 5.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

6.  Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.

Authors:  Yasuyuki Izumi; Yasushi Ami; Kazuhiro Matsuo; Kenji Someya; Tetsutaro Sata; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Kinetics of IFN-gamma and TNF-alpha gene expression and their relationship with disease progression after infection with Mycobacterium tuberculosis in guinea pigs.

Authors:  In Soon Roh; Sungae Cho; Seok-Yong Eum; Sang-Nae Cho
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

8.  Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time.

Authors:  Liya Wassie; Abebech Demissie; Abraham Aseffa; Markos Abebe; Lawrence Yamuah; Hiwot Tilahun; Beyene Petros; Graham Rook; Alimuddin Zumla; Peter Andersen; T Mark Doherty
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

9.  Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions.

Authors:  Maoshui Wang; Zhiqiang Zhang; Xinfeng Wang
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.